Kaempferol
Phase 1Small molecule
Kaempferol is one of 49 small molecule programs targeting Bone Density. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Sexual Dysfunction
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Viibryd
AbbVieApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Buspar
Bristol-Myers SquibbApproved
Estrace
Novo NordiskApproved
Viagra
VViatris Specialty LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Abilify
OtsukaApproved
Requip Xl
GGlaxo Dba Glaxosmithkline
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sexual Dysfunction1 trial
the Ameliorating Effects of Antioxidant Gel on Female Arousal Disorder and Sexual Dysfunction
Completed·—·Phase 1·NCT06060691·30 enrolled
Bone Density1 trial
Kaempferol Gel , Alkaline Phosphatase Activity , Bone Density Around Dental Implants
Completed·—·N/A·NCT07156799·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kaempferol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDeraya University